ATE556092T1 - Mittel zur diagnose und therapie von ctcl - Google Patents

Mittel zur diagnose und therapie von ctcl

Info

Publication number
ATE556092T1
ATE556092T1 AT01271393T AT01271393T ATE556092T1 AT E556092 T1 ATE556092 T1 AT E556092T1 AT 01271393 T AT01271393 T AT 01271393T AT 01271393 T AT01271393 T AT 01271393T AT E556092 T1 ATE556092 T1 AT E556092T1
Authority
AT
Austria
Prior art keywords
ctcl
diagnosis
therapy
agents
novel
Prior art date
Application number
AT01271393T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumselle
Martine Bagot
Allessandro Moretta
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE556092T1 publication Critical patent/ATE556092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01271393T 2000-12-18 2001-12-18 Mittel zur diagnose und therapie von ctcl ATE556092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00403580 2000-12-18
PCT/EP2001/015417 WO2002050122A2 (en) 2000-12-18 2001-12-18 Means for the diagnosis and therapy of ctcl

Publications (1)

Publication Number Publication Date
ATE556092T1 true ATE556092T1 (de) 2012-05-15

Family

ID=8173990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271393T ATE556092T1 (de) 2000-12-18 2001-12-18 Mittel zur diagnose und therapie von ctcl

Country Status (9)

Country Link
US (4) US7399595B2 (de)
EP (1) EP1343822B1 (de)
JP (3) JP2004528824A (de)
AT (1) ATE556092T1 (de)
AU (2) AU1922902A (de)
CA (1) CA2432036C (de)
DK (1) DK1343822T3 (de)
ES (1) ES2387969T3 (de)
WO (1) WO2002050122A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1922902A (en) * 2000-12-18 2002-07-01 Inst Nat Sante Rech Med Novel means for the diagnosis and therapy of CTCL
CN104645327A (zh) 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
US7732131B2 (en) 2004-08-03 2010-06-08 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
WO2007042573A2 (en) * 2005-10-14 2007-04-19 Innate Pharma Compositions and methods for treating proliferative disorders
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
US7917085B2 (en) * 2007-11-09 2011-03-29 Research In Motion Limited System and method for blocking devices from a carrier network
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
WO2009126804A2 (en) * 2008-04-11 2009-10-15 The Regents Of The University Of Colorado, A Body Corporate Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
WO2010081890A1 (en) * 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies
EP2523687B1 (de) 2010-01-15 2017-08-02 INSERM - Institut National de la Santé et de la Recherche Médicale Auf NKp46-Rezeptor gerichtete Verfahren zur Diagnose und Behandlung von kutanen T-Zellen-Lymphomen
WO2012164334A1 (en) 2011-05-31 2012-12-06 Indian Institute Of Technology Madras Electrode and/or capacitor formation
WO2012172102A1 (en) 2011-06-17 2012-12-20 Novo Nordisk A/S Selective elimination of erosive cells
US9024609B2 (en) * 2012-07-11 2015-05-05 Pai Capital Llc Circuit and method for providing hold-up time in a DC-DC converter
CA2881764C (en) * 2012-09-19 2022-08-16 Innate Pharma Kir3dl2 binding agents
ES2770399T3 (es) * 2012-09-19 2020-07-01 Innate Pharma Agentes de unión a KIR3DL2
HUE051988T2 (hu) * 2013-01-07 2021-04-28 Univ Pennsylvania Készítmények és eljárások bõr T-sejt lymphoma kezelésére
WO2014124267A1 (en) 2013-02-07 2014-08-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
DK3521312T3 (da) 2013-02-20 2021-06-28 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
WO2014189138A1 (ja) * 2013-05-23 2014-11-27 Ｉｄａｃセラノスティクス株式会社 免疫不全ウイルス感染の治療又は予防剤
JP6865582B2 (ja) * 2013-05-29 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｋｉｒ３ｄｌ２は皮膚及び非皮膚末梢ｔ細胞リンパ腫のサブセットをそれぞれ予防及び治療するために有用なバイオマーカー及び治療標的である
PL3116908T3 (pl) * 2014-03-14 2020-01-31 Innate Pharma Humanizowane przeciwciała kir3dl2
US20190248895A1 (en) 2016-10-21 2019-08-15 Innate Pharma Treatment with anti-kir3dl2 agents
JP2022523656A (ja) 2019-01-22 2022-04-26 イナート・ファルマ・ソシエテ・アノニム Ｔ細胞リンパ腫の処置
US20240117042A1 (en) 2021-04-05 2024-04-11 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104526C1 (ru) * 1995-05-05 1998-02-10 Эммануил Маркович Коган Способ диагностики т-клеточных лимфом кожи
AU1922902A (en) * 2000-12-18 2002-07-01 Inst Nat Sante Rech Med Novel means for the diagnosis and therapy of CTCL

Also Published As

Publication number Publication date
JP2008261875A (ja) 2008-10-30
EP1343822B1 (de) 2012-05-02
US8518655B2 (en) 2013-08-27
US7399595B2 (en) 2008-07-15
WO2002050122A3 (en) 2003-04-10
US20080274468A1 (en) 2008-11-06
JP5134445B2 (ja) 2013-01-30
US7919085B2 (en) 2011-04-05
AU2002219229B2 (en) 2007-12-20
JP2008289489A (ja) 2008-12-04
JP2004528824A (ja) 2004-09-24
EP1343822A2 (de) 2003-09-17
AU2002219229B9 (en) 2002-07-01
US20120329063A1 (en) 2012-12-27
US20050074761A1 (en) 2005-04-07
ES2387969T3 (es) 2012-10-04
CA2432036A1 (en) 2002-06-27
AU1922902A (en) 2002-07-01
US8268308B2 (en) 2012-09-18
US20110151472A1 (en) 2011-06-23
WO2002050122A2 (en) 2002-06-27
CA2432036C (en) 2018-05-01
DK1343822T3 (da) 2012-08-13

Similar Documents

Publication Publication Date Title
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ECSP055584A (es) Proceso para la preparación de fibrinógeno
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
BG66080B1 (bg) Заместени тиоацетамиди
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
SE9802729D0 (sv) Novel Compounds
SE0301653D0 (sv) Novel compounds
DE602004014361D1 (de) Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE60234354D1 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
DE60115349D1 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
ATE483714T1 (de) Podophyllotoxine als antiproliferative mittel
ATE516356T1 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
ATE554109T1 (de) Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür
ATE374260T1 (de) Asthma-assoziiertes gen
DE50215004D1 (de) Organische verbindungen mit biologischer wirkung als thrombinhemmer und ihre verwendung
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
ATE387913T1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
ATE251619T1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie